BioCentury
ARTICLE | Clinical News

99mTc-rhAnnexin V-128: Phase I/IIa started

January 19, 2015 8:00 AM UTC

Advanced Accelerator Applications began an open-label Phase I/IIa trial to evaluate 0.4 mg IV 99mTc-rhAnnexin V-128 given at day 1 and following treatment with biological DMARD therapies in about 20 p...